Financials Longboard Pharmaceuticals, Inc.

Equities

LBPH

US54300N1037

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
19.72 USD +2.44% Intraday chart for Longboard Pharmaceuticals, Inc. +13.07% +227.03%

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 82.31 56.12 143.9 766.7 - -
Enterprise Value (EV) 1 -24.41 -11.47 143.9 556.7 503.7 476.7
P/E ratio -2.53 x -1.27 x -2.52 x -9.31 x -7.44 x -7.27 x
Yield - - - - - -
Capitalization / Revenue - - - 307 x - 125 x
EV / Revenue - - - 223 x - 77.6 x
EV / EBITDA 0.88 x 0.26 x -2.53 x -6.79 x -4.77 x -5.39 x
EV / FCF - 0.3 x - -8.92 x -5.25 x -4.68 x
FCF Yield - 332% - -11.2% -19% -21.4%
Price to Book - - - - - -
Nbr of stocks (in thousands) 16,867 17,215 23,857 38,878 - -
Reference price 2 4.880 3.260 6.030 19.72 19.72 19.72
Announcement Date 3/3/22 3/2/23 3/12/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - 2.5 - 6.14
EBITDA 1 - -27.84 -44.79 -56.75 -81.94 -105.6 -88.4
EBIT 1 - -27.84 -44.8 -56.76 -77.28 -105.8 -122.5
Operating Margin - - - - -3,091.05% - -1,995.66%
Earnings before Tax (EBT) 1 - -27.8 -43.94 -54.42 -73.9 -103.7 -120.3
Net income 1 -14.4 -27.8 -43.94 -54.42 -73.9 -103.7 -120.3
Net margin - - - - -2,955.9% - -1,959.23%
EPS 2 -5.220 -1.930 -2.560 -2.390 -2.119 -2.652 -2.714
Free Cash Flow 1 - - -38.06 - -62.4 -95.9 -102
FCF margin - - - - -2,496% - -1,660.42%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 2/19/21 3/3/22 3/2/23 3/12/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - - - - - 2.5 - -
EBITDA 1 - - -9.619 -11.56 -11.88 -11.73 -11.96 -15.64 -13.58 -15.57 -15.66 -16.82 -18.16 -19.45 -
EBIT 1 -6.355 -8.794 -9.62 -11.57 -11.88 -11.73 -11.96 -15.64 -13.58 -15.57 -16.38 -17.65 -19.19 -20.57 -
Operating Margin - - - - - - - - - - - - -767.66% - -
Earnings before Tax (EBT) 1 -6.345 -8.773 -9.597 -11.41 -11.6 -11.34 -11.46 -15 -12.93 -15.03 -15.92 -16.36 -17.96 -19.4 -
Net income 1 -6.345 -8.773 -9.597 -11.41 -11.6 -11.34 -11.46 -15 -12.93 -15.03 -15.92 -16.36 -17.96 -19.4 -
Net margin - - - - - - - - - - - - -718.32% - -
EPS 2 -0.3800 -0.5200 -0.5600 -0.6700 -0.6800 -0.6600 -0.5600 -0.6500 -0.5500 -0.6200 -0.4923 -0.4765 -0.4594 -0.5734 -0.5700
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/4/21 3/3/22 5/5/22 8/4/22 11/3/22 3/2/23 5/9/23 8/3/23 11/2/23 3/12/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 107 67.6 - 210 263 290
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - - -38.1 - -62.4 -95.9 -102
ROE (net income / shareholders' equity) - -35.5% -53.3% - -55% -76.7% -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 1 - 0.02 - - - 2.5 2.5
Capex / Sales - - - - - - 40.72%
Announcement Date 2/19/21 3/3/22 3/2/23 3/12/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
19.72 USD
Average target price
42.57 USD
Spread / Average Target
+115.88%
Consensus
  1. Stock Market
  2. Equities
  3. LBPH Stock
  4. Financials Longboard Pharmaceuticals, Inc.